io deep dive survey w/data time
took deep dive intervent oncolog io follow recent
deal includ survey doc find io volum grow mid-teen
liver largest current indic pancrea breast key emerg indic cost
effect well-establish follow-on clinic studi still need theraspher
grow endocar grow rais number
base find
io cancer care nich therapi real disrupt potenti intervent
oncolog io subspecialti intervent radiolog diagnos
therapeut io categori includ embol techniqu occlud block blood
vessel feed tumor abl techniqu use variou energi form
destroy cancer tissu largest current io indic primari metastat
liver cancer embol prostate/ren cancer ablat
io market opportun think could
valu io market today core embolization/abl solut
use mix grow toward compound-annual-growth-rate valu io
grow compound-annual-growth-rate base case market model valu io
today approach use mid-teen volum growth survey
bull model forecast deeper penetr liver support clinic
data indic pancrea breast key driver
io macro find treatment volum grow mid-teen penetr core
liver indic still low grow rapidli hospit econom posit
follow-on clinic studi need unlock expand io use tech find
theraspher prefer select intern radiotherapi sirt therapi
volum expect grow next endocar cs
prefer cryoablat therapi volum expect grow next
rais io outlook survey find bake increment
annual growth btg im growth assumpt account bullish volum
growth expect survey math add annual revenu
still base procedur outlook survey howev
expans indic could render conserv
rais io outlook survey find recent tariff shift also reflect
rais cumul io endocar bead contribut
time-frame base posit survey find revis outlook
call mid-teen io growth prior hsd base growth outlook
endocar survey fulli baked-in benefit recent tariff
exclus could add math
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
summari chang
ep ep exclud extraordinari item amort begin
pleas see import disclosur inform page report
summari find chart io disrupt potenti
take-away deep dive intervent oncolog io survey could approach versu
ascrib addit clinic data unlock new opportun datapoint survey
io procedur outlook mid-teen versu hsd bsx/var data need unlock potenti core liver emerg
indic theraspher forecast grow next endocar cs forecast grow next
exhibit need drive io treatment volum
pleas see import disclosur inform page report
ejef bull cagrour io market model forecast beyond initi outlook total io volum expect increas next year respond survey see io therapi underutil rel exist cancer disciplin surgeri medic overwhelmingli view addit clinic evid import factor drive futur io treatment volum exist new etheraspher sir-spher cdh theraspher volum forecast grow across respond eicefx endocar cs endocar cs ablat volum forecast grow across respond practic equiti research
rais increment
bake higher btg contribut outlook recent enter io space follow close
acquisit uk-bas btg transact ad btg proprietari theraspher microspher sirt icefx cryoablat
solut portfolio follow deal close mid-aug includ new segment model forecast
includ im pharma assum growth im flattish growth pharma crofab
declin also factor pend sale licens segment estim
declin per year slew gener entrant recent sale oncozene/embozen microsphere/bead asset
estim gener revis top-lin outlook bakes-in increment sale
btg theraspher icefx product drive overal organ growth higher time-frame
bake higher io contribut outlook follow fail bid sirtex medic cdh prevail compet
take-ov bid regroup effort ad seri io asset via acquisit privately-held endocar
close earli june coupl recent oncozene/embozen asset purchas close late august
endocar ad solut across ablat embol addit cryocar cs
caligel resorb embol agent respect combin portfolio gener exit base survey find
procedur volum growth add addit contribut top previous baked-
acquir oncozene/embozen asset revis model add increment total io revenu
support survey find
exhibit revis io sale outlook
pleas see import disclosur inform page report
epriorrevisedour revis outlook add increment btg acquisit ebas growthbtg io beaddivestiturejef io bn bn mn mn mn raiseour btg io total contribut prior base bullish find theraspher volum survey io sale mnour revis outlook bake addit combin io revenu begin forecast grow base survey ebas growthiocontributionbeadacquisitionjef io bn bn mn mn bnwe raiseour total io contribut prior base bullish find endocar cs volum survey equiti research
intervent oncolog io landscap thing cancer
therapeut io procedur fall two broad categori embol techniqu occlud block blood vessel feed
tumor kill cancer target ablat techniqu deliv variou form energi heat cryo rf microwav aim
destroy cancer tissu embol abl therapi minimally-invas perform hospit outpati
set largest current indic embol io therapi primari metastat liver cancer prostat renal cancer
abl briefli describ lead io embol abl techniqu snapshot compani posit
applic technolog io glossari appendix contain exhaust list descript
elut bead chemoembol deb-tac select intern radiat therapi sirt techniqu reli use
standard therapeutically-enhanc either chemo-lac radiat embol agent deliv blood vessel adjac
cancer site order prevent/block blood flow tumor result blood occlus embed embol particl
result tumor hypoxia starvat select case necrosi death without impact healthy/norm surround structur
select lead io embol technolog includ theraspher microspher acquir btg sir-spher
microspher acquir cdh-privat embospher microspher merit medic nc oncozene/embozen spheres/bead
acquir
lead io ablat therapi includ radiofrequ rf ablat cryoablat microwav ablat mva high-
intens focus ultrasound hifu ablat techniqu reli variou form energi deliv either
minimally-invas non-invas tumor site order bring cellular apoptosi select case tumor necrosi
rf reli deliveri electr produc ionic friction caus cellular destruct cryoablat bring instant cell death
via instant signific temperatur reduct mva use electromagnet energi promot high frequenc
oscil water molecul cell result clot hifu use focus ultrasound wave heat eventu destroy
select lead io ablat technolog endocar cs cryoablat acquir endocar icefx cryoablat
acquir btg neuwav mva jnj-ethicon emprint mva mdt-covidien
exhibit intervent oncolog io categori product landscap
pleas see import disclosur inform page report
interventionaloncolog roadmap diagnost io descriptionprocedur obtain diagnos suspect cancer tissu neoplasmsselect diagnost io techniques-fin needl aspiration-cor need biopsy-vacuum assist biopsypalli io descript io procedur use advanc case option manag pain select palli io techniqu -stent re-open impact ducts-plasma-medi coblation-combin therapi tae ablat io embol descriptionprocedur treat/kil cancer block blood vessel tumor growthselect diagnost io techniques-bland embol tae -transateri chemoemobl tace -drug elut bead chemo deb-tac ioablat descriptionppprocedur treat/kil cancer use energi tissu destructionselect ioablat techniques-cryoablation-radiofrequ ablat rfa -microwav ablat mva equiti research
 flurri io space well-posit follow recent deal
sever recent deal varian made io increasingli import segment med-tech investor first
made move bid jan sirtex medic later acquir cdh invest june
shortli cdh sirtex announc launch bid btg close earlier year aug later
enter io space dual take-out privately-held endocar give access nich cryo bead solut june
recent sold sever micro-spher bead asset part ftc review close btg aug
exhibit recap intervent oncolog io activ
pleas see import disclosur inform page report
varian medic mna part ftc review btg requir sell microspher oncozene/embozen tandem bland embol embozen bead asset gener revenu varian medic mnalicon lead product caligel calibr resorb gelform particl use embol agent china treat liver cancer caligel use major hospit china treat patient annual endocar varian medic mnendocar lead product cryocar cssystem fulli integr cryotherapi tissu ablat solutionaim treat wide rang cancer includ prostat kidney lung liver metastas palli bn btg io franchis includ theraspher radiotherapi microspher galil cryoablat system use treat liver kidney cancer sirtex medic cdh bn cdh invest chines invest consortium outbid varian prior offer offer sirtex medic varian medic bn varian sign agreement acquir sirtex medic cash sirtex sir-spher resin microspher fda clear treat unresect metastat liver cancer primari crc galil medic mn us galil medic product indic treatment palli care kidney cancer clinic program us clearanc lung bone metastas on-going time deal neuwav medic johnson johnson neuwav system perform singl simultan multipl probe procedur patient soft tissu lesion use irrevers electropor ire ablaton techniquetargetacquirerclos datepurchas priced descript equiti research
lead cancer treat embol io therapi hepatocellular carcinoma primari liver cancer given natur
blood suppli rout target organ normal liver receiv blood flow hepat arteri portal
vein tumor develop liver becom depend blood hepat arteri henc embol technolog
design block blood suppli origin combo therapi work simultan bring cancer cell starvat
sirt radioembol lead io embol techniqu current deploy interventionalist technolog work
deliv high dose beta-radi microspher directli liver tumor via transfemor microcathet
hepat arteri lead solut treatment categori sirtex medic sir-spher acquir cdh theraspher
acquir use enhanc microparticl irradi liver tumor differ sir-spher
theraspher includ materi composit resin vs glass locat radioact isotop within materi
exhibit sirt embol product featur
cryoablat minim invas treatment use extrem cold freez destroy diseas tissu cryoablat
high pressur ga circul needle-lik applic local freez tissu result energi deprav drop
surround temperatur caus cell death endocar cryocar cs acquir icefx acquir
two cryoablat system approv oncolog ablat well varieti indic cryoablat requir
continu imag monitor tissu coverag varieti differ size probe target specif cancer endocar cs
equip integr ultrasound system wider probe portfolio
exhibit cryoablat product featur
pleas see import disclosur inform page report
sir-spheressirtex medicalresin g/dl bound resin surfacepma colorect metastas combin chemotherapytheraspher boston scientif formerli btg glass g/dl incorpor glass matrixhumanitarian devic exempt hepatocellular carcinoma microspher per gbq vial isotop indicationskey featuresgrav bloodact per particl mean diametermateri manufacturersirt devicescryocar cs varian formerli endocar argon helium helium angl ultrasoundabl malign benign tumor palli interventionabl prostat tissu case prostat cancer urolog dermatolog gyn gener surgeri ent thorac proctologyicefx boston scientif formerli btg argon angl malign benign tumor palli interventionabl prostat tissu case prostat cancer urolog dermatolog gyn gener surgeri ent thorac proctologykey featuresoth indicationsoth featur manufacturerga suppli temperatur produc needl configur puriti leveloncolog indicationscryoablationdevic equiti research
io clinic snapshot readout on-going studi sirt
inoper liver tumor associ either mcrc commonli treat chemotherapi specif folfox
folfox leucovorin fluorouracil oxaliplatin sorafenib accordingli sirtex medic conduct seri phase open-label
random trial evalu safeti efficaci sir-spher resin microspher combin chemotherapi
treatment liver domin mcrc across sever thousand patient collect trial demonstr
statist signific superior overal surviv os progression-fre surviv two indic studi find
sirt chemo demonstr better liver tumor respons rate chemotherapi alon moreov studi show
combo sirt chemo interfer system chemo total toxic remain accept rang certain case
sarah translat significantli better health relat qualiti life hrqol
likewis btg acquir august run two phase open-label random trial compar sirt technolog
theraspher glass microspher chemo versu chemo alon mcrc trial current on-going
definit total sirt chemo studi indic io promis therapi two extrem hard treat liver cancer
signific interest investig use sirt number addit indic includ primari renal metastat
breast metastat pancreat metastat neuroendocrin cancer
exhibit comparison complet on-going sirt clinic studi
pleas see import disclosur inform page report
stop-btg phase open-label random studi compar sorafenib theraspher vs sorafenib alon unresect hepatocellular carcinoma overal respons os assess month open-label random studi compar theraspher oxaliplatin-/irinotecan-bas chemo chemo alon follow fail first line chemo metastat colorect carcinoma mcrc progression-fre surviv assess mosliv specif progression-fre surviv analysissirtex medic cdh invest combin data analysi sirflox foxfir foxfir global studi patient diagnos unresect mcrc liver alon liver addit site lung lymph node overal respons os assess mosprogression-fre surviv liver specif respons resect medic cdh invest phase open-label random studi compar sir-spher vs alon first line therapi treat nonresect liver metastas primari crcprogression-fre surviv assess mosoveral respons os assess medic cdh invest phase open-label random studi compar oxmdg sir-spher vs oxmdg alon first line therapi unresect primari liver liver domin mcrcoveral respons os assess mosprogression-fre surviv liver specif respons resect global sirtex medic cdh invest phase open-label random studi compar sir-spher vs alon first line therapi orr treat nonresect liver metastas primari crcoveral respons os assess mosprogression-fre surviv assess medic cdh invest phase ii double-blind random studi compar sorafenib sir-spher vs sorafenib alon palli cohortoveral respons os assess mossafeti qualiti life medic cdh invest phase open-label random studi compar sorafenib sir-spher advanc overal respons os enrol mortalitysafeti toxic qualiti life qali medic cdh invest phase open-label random studi compar sirt sorafenib local advanc overal respons os assess month progression-fre surviv liver specif endpoint -- ongoingmedian os control sirt median mo mo control sirt os mo sirt control sponsorsirt studystudi descript primari endpointsecondari endpointsitt subject median mo control sirt control sirt os mo mo control sirt mo mo control sirt stat sig differ median os stat sig differ median os result summari primari endpoint equiti research
io clinic snapshot readout on-going studi cryoablat
cryoablat clinic trial conduct broad rang cancer includ metastat lung primari renal primari
recurr prostat cancer well pain palliat bone metastas method action highli concentr
primari secondari endpoint clinic trial focu tumor control recurr rate local level cryoablat
current approv number indic includ skin tumor non-resect prostat liver cervic cancer sever
galil medic acquir btg may conduct seri cryoablat clinic trial metastat lung cancer pain
palliat bone metastas accept safeti profil suffici tumor control local level although statist
signific shown singl arm trial icefx cryoablat system grant approv us fda via
pathway icefx cryoablat system indic
urolog ablat prostat tissu prostat cancer bph
oncolog ablat cancer tissu benign tumor palli intervent
ent palliat oral caviti tumor
thorac surgeri exclud cardiac tissu
gener surgeri palliat rectal tumor
cryocar cs varian likewis fda approv indic icefx includ cardiac tissu ablat
cryoablat yet establish breast cancer howev sanaru technolog privat current run phase
ii clinic trial use minim invas visica treatment evalu cryoablat altern earli stage invas
breast cancer visica treatment fda clear use patient
exhibit comparison complet on-going cryoablat clinic studi
pleas see import disclosur inform page report
frostsanaru technologiesnon-random open-label trial evalu cryoablat altern surgeri treatment earli stage invas breast cancer tumor ablat occurr assess mosloc tumor recurr assess medic btg open label single-arm studi evalu safeti effiaci cryoablat treat tumor pulmonari metastat diseaseoveral local tumor control assess mo tumor number patient sever advers event medic btg phase prospect single-arm studi evalu safeti efficaci cryoablat metastat lung/pleura tumor overal local tumor control assess mo overal surviv os assess medic btg open label single-arm trial evalu efficaci cryoablat palliat pain bone metastas chang baselin worst pain score week particip respond et al analysi laparoscop renal cryoablat first treatment small renal yr local recurrence- free surviv rf yr system progression-fre surviv et al n/aretrospect analysi laparoscop renal cryoablat first treatment small renal tumorsoveral local tumor control assess mostumor size local relaps asscoci et al pharmaceuticalsprospect analysi diseas specif outcom salavg cryotherapi local recurr prostat cancer within registrybiochem disease-fre surviv bdf rate et al pharmaceuticalsprospect analysi diseas specif outcom treatment nave patient underw primari whole gland prostat cryoablat within yr bdf rate amico risk subject cryoablat studycompani sponsorstudi descript primari endpointsecondari endpointsstudi result summari primari endpointsecondari overal local tumor control patient overal local tumor control mo median associ bet tumor size local relaps bdf yr respectively-low intermedi high overal local tumor control os mo stat sig differ pain patient respond cryoablat mo median local recurr rf mo median relaps yr equiti research
io clinic snapshot readout on-going studi microwav ablat
sever microwav ablat system clear market us fda via pathway includ covidien
acquir evid emprint microwav ablat system use percutan laparoscop intraop soft
tissu ablat includ partial complet ablat non-resect liver tumor follow devic also receiv
clearanc microwav ablat unspecifi soft tissu
valleylab subsidiari covidien vivawav microwav ablat system
microsuli medic acculi
neuwav medic ethicon
neuwav medic ethicon neuwav flex microwav ablat system accessori
fda determin system substanti equival exist predic devic base variou intern
standard non-clin perform data bench verif test product stabil test biocompat test valid
ethicon current market microwav ablat devic simultan conduct evalu
respect microwav ablat devic post-market trial specif patient popul china korea
exhibit comparison microwav ablat complet on-going clinic studi
pleas see import disclosur inform page report
ciemarmdt observ clinic use emprint microwav ablat system ablat liver metastas colorect adenocarcinomaloc tumor control assess mosoveral surviv os overal disease-fre surviv assess random single-blind studi prove non-inferior thermal ablat compar hepat resect patient colorect liver metastasesoveral surviv os assess yrsdiseas free surviv time progress assess yr neuwav medic single-arm open-label prospect studi evalu safeti effect neuwav certu microwav ablat system chines patient hepatocellular carcinoma technic success assess day post-procedureprimari technic efficaci assess mo confirmationethicon neuwav medic single-arm open label studi evalu neuwav microwav ablat system ablat confirm ac softwar treatment soft tissu liver lesionspercentag patient probe reposit re-abl suggestedr advers event ae technic success flex neuwav medic single-arm open label studi evalu neuwav flex microwav ablat system treatment secondari soft tissu lesion lung devic user experi surveytechn success efficaci advers event ablat patient koreaethicon neuwav medic open-label single-arm non-random studi evalu microwav ablat patient korea subject achiev tumor ablat assess day post-treat subject achiev tumor ablat assess day microwav ablat studycompani sponsorstudi descript primari endpointsecondari endpointsitt subject studi result summari primari endpointsecondari endpointongo on-going on-going on-going on-going equiti research
io clinic snapshot readout on-going studi radiofrequ ablat
high intens focus ultrasound ablat
radiofrequ ablat rfa image-guid minim invas techniqu reli deliveri electr produc ionic
friction caus cellular destruct surround electrod rfa wide avail long track record collect data
consider cheaper newer ablat modal consider awar among oncologist number
fda approv rfa system avail us includ
covidien acquir june valleylab rfa gener cool-tip technolog
rf rfa gener leveen needl electrod famili
model rfa gener starburst habib electrosurg devic ablat soft tissu coagul
rfa demonstr safe feasibl treatment primari unrespect rfa also use treat
recurr diseas report year overal surviv os rate rang also disadvantag rfa
skin pad burn concern needl tract seed heat sink effect cool properti hepat blood flow attribut
tumor recurr ablat size limit larger lesion limit led develop ablat
techniqu use heat well combin chemotherapi celsion
high-intens focus ultrasound hifu new non-invasive imag guid treatment use focus ultrasound wave thermal
ablat diseas tissu hifu use sonic sound energi creat heat target soft tissu caus necrosi edap privat
albatherm fusion focal one also market fda approv prostat ablat cancer therapi
exhibit comparison rfa complet on-going clinic studi
exhibit comparison hifu complet on-going clinic studi
pleas see import disclosur inform page report
thermodox w/ rfa celsionphas random blind studi evalu compar rfa thermodox thermal sensit liposom doxorubicin rfa alon treat inoper hepatocellular carcinoma progress free surviv assess yr overal surviv os assess et al prospect nonrandom studi evalu rfa primari metastat lesionscompl ratetumor open label studi evalu radiofrequ ablat rfa breast lumpectomi site extend intraop margin treatment breast cancerestim re-excis rate close posit margin decreas local recurr assess et al compar studi evalu unresect patient treat rfa taceoveral surviv rate assess unresect nci studi n/a phase ii singl arm open label trial studi evalu rfa primari metastat lesionsrespons time frame unknown advers event subject rf studycompani sponsorstudi descript primari endpointsecondari endpointsstudi result summari primari endpointsecondari yr os rfa tace mo mo control combin complic liver tumor recurr lesion progress diseas incr diamet lesion -farpedaprandom open-label trial compar hifu ablat radic prostatectomi treatment prostat cancertreat failur assess month urinari prostat cancer edapsingl arm open label studi evalu use hifu treatment nave prostat cancermean reduct yrsadvers event profound medicalpivot singl arm studi evalu safeti effiaci mri-guid transurethr ultrasound therapi tulsa-pro ablat prostat tissu local prostat cancerincid treatment-rel advers event ae proport patient achiev nadir pre-treat baselin yr erectil dysfunct urinari incontin subject ongoingongo hifu studycompani sponsorstudi descript primari endpointsecondari endpointsstudi result summari primari endpointsecondari endpoint equiti research
order better understand market dynam across io landscap survey high-volum intervent radiologist
outlook procedur volum trend key advantag disadvantag versu cancer care modal medic rt
surgeri barrier wide-scal adopt technolog prefer across larger sirt cryoablat segment
final survey sampl includ doc averag post-resid practic year experi varieti diagnostic/
therapeut io techniqu high annual procedur volum perform io intervent per year
given current io focu advanc stage cancer surpris see treat case consid
unresect mix even mix primari metastat condit primari vs metastat treatment
mix cancer type also surpris in-line current approv indic embol ablat techniqu
case treat either primari metastat liver cancer coincid primari indic sever embol techniqu
follow kidney cancer also coincid clearanc embol ablat although lung current
indic certain embol therapi surpris see rank third common io treat cancer survey
case ahead primari colorect case consid liver secondari metastat colorect cancer mcrc
cover indic mix io treatment techniqu well balanc activ perform varieti ablat rf
microwav cryoablat embol tae tace deb-tac sirt diagnost needl aspir needl biopsi vacuum-
assit biopsi io techniqu technolog standpoint nearli respond experi use theraspher
icefx cryoablat solut along endocar cryocar cs
exhibit averag mix io surgeri perform
exhibit averag mix io surgeri perform
exhibit averag io treatment mix cancer
pleas see import disclosur inform page report
cancersunresect io surgeri perform unresect cancersmetastat cancersnearli even split among cancer type treat io largest percentag procedur perform ablationtaetacedeb-tacesirtothersirt util io therapi follow ablat among respond equiti research
deeper look current io trend rapid growth still heavili underutil
look deeper current market trend ask respond stack rank io intervent procedur volum lead indic
embol ablat therapi hepatocellular carcinoma metastat colorect cancer mcrc renal cell
carcinoma metastat neuroendocrin tumor mnet hepatocellular carcinoma wide treat cancer
averag mix follow metastat colorect cancer mcrc averag coincid on-label
indic select embol therapi sirt deb-tac other beyond mcrc renal cell carcinoma account
treat case follow metastat neuroendocrin tumor mix coincid indic ablat
treatment volum front sampl interventionalist perform averag nearli procedur per month
albeit high rang hand respond treat fewer case sever perform case total
physician sampl perform averag north case per month prior year ask respond
forecast forese monthli io treatment volum trend next receiv bullish feedback
volum expect increas follow compound-annual-growth-rate volum round
despit outlook appear acceler growth io procedur volum nearli respond survey see
io therapi underutil versu exist big cancer treatment categori medic surgeri radiat rt surprisingli
respond felt io treatment approach underutil two on-label indic liver kidney indic still healthi room
expans core patient market beyond liver kidney respond saw io underutil lung follow
bone met posit indic futur market expans opportun
exhibit io underutil
pleas see import disclosur inform page report
mcrc renal cellcarcinomametastaticneuroendocrinetumorsotherrespond note major io procedur perform hepatocellula carcinoma metast colorect total io volum expect increas next year respond survey see io therapi underutil rel exist cancer disciplin surgeri medic respond note lung under-util cancer follow liver kidney equiti research
deeper look io under-util data protocol awar
provid raw comment respond view three signific applic io
therapi current underutil lung liver kidney within lung common feedback rt well establish
case caus ablat particular pass viabl treatment option within liver feedback favor
embol lack patient awar patient ownership surgeon radonc insur coverag common factor
limit usag kidney common feedback lack patient referr primari point care urologist
set
exhibit qualit respons io under-util select cancer
pleas see import disclosur inform page report
countcanc io need aggress cancer patient lung cancer emphysema radiat decreas lung function data lung ablat much support nation believ ablat standard resect ablat proven well establish lung reluct give ground abl vs sbrt refer ablat trainwreck patient oncologist believ lung therapi histor popular io treatment sbrt gain physician lack knowledg comfort less literatur radiat even consid oncologist valid ablat limit role rare pt undergo sbrt less util ablat much awar clinic cur mani therapi first line cours treatment deal cancer liver want cut oncologist want give chemo and/or enrol trial liver direct therapi may best coverag patient med onc mostli system therapi truli local diseas case numer approach liver lesion includ surgerri chemo sbrt get paid transarteri embol system io therapi injur liver patient receiv system much emphasi chemo surgeri fals assumpt alway palli good data efficaci embol ablat seed hepatocellular much awar local palli term relationship urologist patient limit mention io therapi use vs partial nephrectomi often refer ablat poor candid urologist control quick remov entir kidney sinc typic two get paid pattern urologist safe collect outcom lower risk lesion equiti research
io underutil closer look advantag vs disadvantag
report number compani space approxim io market revenu provid
suggest lsd penetr view among respond point toward signific level under-util
io therapi attempt flesh dispar lie explor physician view competit advantag versu
disadvantag categori versu cancer care modal common advantag io report respond
around benefit minim invas therapi versu invas surgic treatment system medic treatment
chemotherapi sever benefit stem minim invas includ better toler shorter recoveri time
less toxic fewer complic better patient qualiti life lower cost also list advantag
exhibit qualit respons advantag io therapi
pleas see import disclosur inform page report
therapi effect case non surgic therapi allow us minim invas highli select minim damag surround life advantag complet outpati visit life minim invas invas complic minim side effects/tox well toler good clinic invas potenti cur therapi patient popul may candid invas quick recoveri less risk advers event proven care evid base support ir procedur recoveri offer patient surgic option focal local effici invas less patient downtim fewer risk compar surgeri less toxicity/sid high dose minim risk normal visit quick local potenti target invas minim invas well toxic local intern radiat side effect invas precis quick morbid less loss time last month life rapid response/improv fewer complic properli select patient equival long term result invas less toxic faster need gener anesthesia faster invas lead less recoveri time invas less pain recoveri time perform patient unabl undergo surgeri usual singl session invas well toler side effect standpoint outpati typic requir multpil session morbid better toler system chemotherapi immedi respons radiat bone smaller suprior regard manag tumor ablat therapi one time treatment invas quicker therapi local lower risk advers event versu system therapi mani case delay chemotherapi use toler without damag tissu respons well patient morbid less time hospit patient invas invas similar outcom rcc similar outcom xrt ablat lung malign better chemo less invas well toler high risk patient equiti research
io disadvantag lack level clinic evid
despit respond cite sever distinct advantag favor io tradit cancer therapi particularli
advanc case surgeri system chemotherapi viabl option feedback disadvantag seem zero-in
sever notabl disadvantag two big class io therapi embol ablat well overal categori
ablat common shortcom around limit size treatabl lesion approach microwav
rf cryo embol need skill team vascular access surgeon schedul common disadvantag
across entir io categori sever disadvantag list includ potenti damag target organ need repeat
procedur limit advanc case list beyond common disadvantag lack level clinic
evid long-term surviv data support io tradit cancer therapi medic surgic rt
exhibit qualit respons disadvantag io therapi
pleas see import disclosur inform page report
therapi invas radiat medic io therapi cur case evid support use therefor referr less like send patient radiat level evid neg unknown use io therapi combin cancer cur limit addit clinic data procedur procedur schedul barrier adopt due procedur take place outsid avail technolog cur vs low risk good surgic patient candid io therapi minim invas still involv limit procedur requir vascular access skill indirect treatment malign left bodi mean technic system effect drastic effect target cur like data particularli regard surviv given option surgeon tri perform offer open refer patient surgic candid therefor higher risk baselin poorer invas radiat less data potenti need repeat procedur requir multipl resect gold mani case possibl organ failur due provid meaning surviv benefit compar tradit treatment diseas advanc sophist techniqu associ embol syndrom requir hospitalizion pca extens work-up room error fluoro often somewhat invas administr time protocol intens iv oral therapi complet kill cancer achiev clean margin surgic suit possibl insur denial clinic data invas potenti incomplet tumor durabl favor outcom target issu equiti research
data current new indic open io opportun
dug deeper explor reason under-util io therapi see factor beyond lack clinic evid
key barrier wider-scal adopt order ask respond stack rank sever io product featur need
improv order facilit wider-scal adopt scale import import specif io
featur better imag guidanc solut drug deliveri devic treatment plan softwar tp rank
indic least room improv exist datapoint tp specif in-line outlook potenti
revenu synergi exist marri expertis softwar plan acquir endocar alicon io solut common
barrier adopt list qualit feedback better physician train rank rang among respond
need improv order unlock futur adopt surprisingli wider-scal reimburs support also cite despit
attract econom current place profit embol ablat base survey data take-away
hospit econom current favor addit clinic evid facilit seamless reimburs
despit sever product featur rank rel high among respond area futur improv clinic
evid also quantit rank highest concern around lack clinic evid stem sever
fail studi sirt combo therapi mcrc lead competitor sirtex medic sirflox foxfir foxfir global
along fail readout btg motion studi palli bone metastasi open-label singl arm studi
enter space via acquisit co talk revamp clinic dossier around key io asset
acquir btg endocar deal respect look ahead sever key readout next year
embol epoch stop-hcc studi phase open label combo-therapi studi non-random
open-label frost studi cryoablat posit read studi would expect collect data provid
suffici support increas usag time see rct section detail
exhibit need order increas io therapi util need import
pleas see import disclosur inform page report
overwhelmingli view addit clinic evid import factor drive futur io treatment volum exist new cancer equiti research
embol io trend outlook posit sirt theraspher
beyond multi-year macro theme explor near-term io technolog prefer trend among respond captur survey
order gain better perspect growth outlook recent close btg acquisit recent close endocar
deal first ask respond stack rank prefer among variou io embol tae deb-tac tace
sirt io ablat fr mva cryotheraphi hifu techniqu provid detail specif tech prefer within
bucket
within io embol categori prefer treatment techniqu select intern radiat therapi
respond rank sirt heavili use io treatment techniqu within practic follow prefer
transarteri chemoembol tace drug elut bead chemoembol deb-tac expect
commonli treat cancer sirt lead on-label indic hepatocellular carcinoma follow metastat
colorect cancer mcrc liver metastasi treatment mix similar tace deb-tac sever
respond indic lung metastat neuroendocrin tumor net use select case
exhibit follow io embol technolog
use practic
exhibit sirt technolog current use
often practic
within sirt specif categori acquir theraspher glass microspher compet sir-spher resin
microspher nearli equal favor among respond although sever note better hepat arteri blood flow clinic
data support therespher slightli better hospit econom also favor theraspher due lower price
standpoint hospit gener profit singl dose theraspher treatment
reimburs sphere code pretreat map angiographi post-treat imag factor
exhibit average cost per dose follow sirt product
pleas see import disclosur inform page report
respond use sirt prefer io embol therapi practic follow tace sir-spher cdh noyestheraspher sir-spher util high across sampl sir-spher cdh cost per dose boston theraspher less rel compet sirtex microspher dosessir-spher cdh theraspher average reimburs per sirt procedur across sampl eva theraspher slightli higher lower cost equiti research
overal feedback io volum bullish expect grow mid-teen still heavili underutil feedback sirt
within embol posit want gain better understand near-term growth outlook two lead solut
space recent acquir theraspher microspher sir-spher microspher specif
ask respond provid procedur volum growth outlook technolog feedback
bullish expect ahead initi growth target provid time acquisit im busi grow
btg deal announc late
compet cdh sir-spher microspher respond forecast procedur volum growth
similarli respond forecast procedur volum growth theraspher
suggest uplift sirt categori rise tide carri boat moment look survey feedback
broadli io sirt specif see potenti product categori alon surpass time current
uptak core liver indic advanc cancer pancrea lung prostat acceler
exhibit outlook sirt procedur volum
pleas see import disclosur inform page report
etheraspher sir-spher cdh theraspher volum forecast grow across respond practic equiti research
ablat io trend outlook posit cryo
within io ablat categori sever techniqu rank high often perform respond particip
survey among cryoablat use extrem cold destroy target tissu microwav ablat mva use electromagnet
energi heat/destroy target tissu radiofrequ ablat rf use electr destroy target tissu captur
equal weight util practic repres respond follow averag weight
irrevers electropor ire use ultra short electr puls disrupt cellular homeostasi averag weight
io ablat techniqu chemic laser hifu commonli treat cancer cryoablat advanc renal
cell carcinoma rcc lesser extent primari metastat liver hand respond also list lung prostat bone
target cancer cryoablat mva commonli treat cancer primari metastat liver follow lung
hand respond also referenc renal target indic rf common cancer also liver kidney
follow bone metastasi
exhibit follow io ablat technolog
use practic
exhibit cryoablat technolog use
practic
within cryoablat categori recent acquir endocar cs system prefer among respond activ
use practic versu recent acquir icefx system respond activ use practic
common qualit featur mention regard prefer endocar icefx abil simultan use wide
varieti probe creat larger freez zone overal effect slightli better hospit econom also favor endocar
due lower price standpoint hospit gener profit singl session endocar treatment
multipl session setup imag treatment plan treatment factor
exhibit average cost per treatment follow cryo product
pleas see import disclosur inform page report
rf prefer ablat therapi among respond cs icefx yesno endocar cs heavili adopt cryoablat solut across sampl cs icefx average cost per treatment varian theraspher less rel boston icefx cryo probe sessionmultipl sessionsicefx endocar cs average reimburs per cryo procedur across sampl endocar slightli higher lower cost equiti research
similar thought process io embol feedback underli io trend cryoablat specif among
ablat therapi posit want gain better understand near-term growth outlook two lead solut
space recent acquir endocar cs cryoablat icefx cryoablat specif ask
respond provid procedur volum growth outlook technolog feedback also
bullish expect ahead initi growth target provid time respect acquisit
initi model growth endocar btg im busi grow deal announc
late
outlook procedur volum icefx system among respond
endocar cs respond forecast procedur volum growth suggest
system remain prefer cryotherapi ablat system tumor ablat least next look survey
feedback broadli io cryoablat specif see potenti product categori surpass time
current uptak rcc liver soft tissu metastasi acceler
exhibit outlook cryoablat procedur volum
pleas see import disclosur inform page report
eicefx endocar cs endocar cs ablat volum forecast grow across respond practic equiti research
io base market model approach indic
valu io market today grow per year inclus core embolization/abl solut plu enabl
equip coil guidewir cathet assum mix core solut point toward exit compound-annual-growth-rate
valu io today inclus core solut compound-annual-growth-rate attempt confirm
figur build top-down market model begin diseas preval incid mortal statist top on-label
cancer treat use variou io techniqu ablat embol back current penetr estim
consid price data lead ablat embol techniqu sourc survey versu recent report sale
figur sever public privat compani btg sirtex medic endocar merit medic other approach yield total
avail market size core io solut close current market valu updat
input driver base case model includ
us global annual incid rate current approv io indic
hepatocellular carcinoma ww incid us
metastat colorect cancer mcrc ww incid us
mestastat neuroendocrin tumor mnet ww incid us
us global incid primari metastat liver factor base case model ww incid
total ww target patient io therapi core indic estim expand
patient elig tradit cancer therapi surgeri medic rt ncd iowa registri
total ww avail patient io therapi estim reach ww target
base case assum penetr target io patient treat ablat embol respect
use treatment per case sourc io survey translat total io treatment core indic
io therapi mix split cryoablat ablat therapi cryo gain modest share
io therapi mix skew sirt core embol treatment vs embol therapi maintain share
cryoablat asp per treatment sirt asp per treatment blend asp io techniqu
base case io core model point
pleas see import disclosur inform page report
pleas see import disclosur inform page report
us hepatocellular carcinoma ww liver annual ww annual hepatocellular carcinoma ww annual ww liver annual mortal rate primari metastat liver cancer ww liver annual liver cancer growth annual annual mortal rate metastat colorect cancer mcrc incid ww mcrc metastat colorect cancer mcrc incid ww mcrc metastat colorect cancer mcrc incid growth annual annual mortal rate metastat neuroendocrin mnet incid ww mnet metastat neuroendocrin mnet incid ww mnet metastat neuroendocrin tumor mnet incid growth annual annual mortal rate us target patient io therapi ou target patient io therapi target patient io therapi core patient elig therapi elig surgeri non-respons chemotherapi region elig rt elig liver transplant patient elig tradit cancer avail patient io total target lead growth target patient treat w/ follow io therapi treat w/ annual penetr treat w/ embol annual penetr estim ablat estim embol estim io treat patient core treatment per io estim io ablat treatment core estim io embol treatment core estim io treatment core core io therapi mix cryoablat mix core io ablat annual mix ablat sirt mix core io embol annual mix embol estim cryoablat estim sirt per cryoablat treatment annual asp per sirt treatment annual asp per io treatment cryoablat sirt io therapi estim io y/i market model equiti research
io bull case market model surpass w/data new indic
use sever key find survey driver deriv bull case io market recal nearli respond
survey see io underutil versu big three cancer care modal surgeri medic rt see exhibit
dug deeper topic ask respond cancer see ablat embol techniqu under-
util despit liver kidney on-label ablat embol respond still view indic
under-serv io henc key futur growth driver solut look beyond on-label indic soft tissu
metastat diseas broadli view appropri io techniqu breast pancrea prostat list futur
exhibit indic see primari growth
driver io ablat
exhibit indic drive growth io embol
use mani start driver bull case model except ad margin penetr
common off-label indic referenc survey specif bake preval incid mortal lung prostat
pancrea order gaug upsid potenti io ablat embol non-cor indic think evolv
clinic evid time approach yield total avail market size across target indic
today versu current forecast nearli exit versu forecast
input driver bull case model includ
us global annual incid rate new indic develop
lung ww incid us
prostat ww incid us
pancreat ww incid us
ww patient io therapi addit indic estim expand
patient elig tradit cancer therapi surgeri liver transplant etc ncd iowa registri
target ww avail patient io therapi estim grow
assum penetr target io patient treat ablat embol respect
use treatment per case translat addit io treatment non-cor indic
io therapi mix split cryoablat ablat therapi cryoabat gain modest share
io therapi mix skew sirt core embol treatment vs embol therapi maintain share
cryoablat asp per treatment sirt asp per treatment blend asp io techniqu
bull case io model point versu ascrib
base case model addit io indic ad forecast
pleas see import disclosur inform page report
respond see deeper penetr liver lung cancer primari driver growth ablat therapi bone breast list key futur indic respond see deeper penetr liver cancer mcrc driver growth embol pancrea prostat list key futur indic exhibit bull case io market model
pleas see import disclosur inform page report
us lung cancer incid ww lung cancer lung cancer incid ww lung cancer lung cancer incid growth annual annual mortal rate prostat cancer incid ww prostat prostat cancer incid ww prostat prostat cancer incid growth annual annual mortal rate pancreat cancer incid ww pancreat pancreat cancer incid ww pancreat pancreat cancer incid growth annual annual mortal rate us target patient io therapi ou target patient io therapi target patient io therapi non-cor patient elig therapi elig surgeri non-respons chemotherapi region elig rt elig liver transplant patient elig tradit cancer avail patient io total target lead growth target patient treat w/ follow io therapi treat w/ annual penetr treat w/ embol annual penetr estim ablat estim embol estim io treat patient follow-on treatment per io estim io ablat treatment core estim io embol treatment core estim io treatment follow-on follow-on io therapi mix cryoablat mix follow-on io ablat annual mix ablat sirt mix follow-on io embol annual mix embol estim cryoablat estim sirt per cryoablat treatment annual asp per sirt treatment annual asp per io treatment cryoablat sirt io therapi estim io follow-on indic case estim io case estim io y/i bull market model equiti research
glossari io term use report
provid glossari intervent oncolog io terminolog use throughout report use quick refer
guid get speed variou approach technolog employ area cancer care
chemic ablat ablat techniqu use ethanol acet acid inject tumor caus protein denatur cell death
radiofrequ ablat tissu destruct heat gener medium frequenc altern current
irrevers electropor ultra short electr field creat perman lethal nanopor cell lead cell death
cryoablat hollow needl freez cell temperatur degre celsiu caus instant cell death
microwav ablat electromagnet wave produc tissue-h effect lead cell death
high-intens focus ultrasound hifu target beam non-ion ultrason wave heat tissu destroy cell
bland embol inject embol agent deliv tumor feed arteri occlud blood suppli
transarteri chemoembol tace inject chemotherapi agent embol bead liver produc ischemia
drug elut bead chemoembol deb-tac inject chemotherapi coat embol bead allow prolong drug
elut ischemia
select intern radiat therapi sirt also refer transarteri radioembol tare procedur perform
intervent radiologist microspher impregn inject arteri suppli malign
tumor techniqu significantli prolong time-to-progress ttp hepatocellular carcinoma toler advers event
profil improv patient qualiti life rel io therapi
intra-arteri chemotherapi high dose chemotherapi administ directli feed arteri tumor
portal vein embol pve inject embol block materi portal vein occlud block blood flow tumor
radiat lobectomi inject small radioact bead hepat arteri feed hepat lobe tumor locat
decay product fission product uranium sourc nuclear reactor
glossari cancer term use report
provid glossari gener cancer terminolog use throughout report supplement io specif glossari
hepatocellular carcinoma common type primari liver cancer adult common caus death peopl
cirrhosi evolv presenc chronic liver inflamm associ chronic viral hepat hep
exposur variou toxin alcohol carcinogen
metastat colorect cancer mcrc occur cancer cell break away primari tumor colon rectum
spread part bodi blood stream lymphat system common site metastas liver
metastat neuroendocrin tumor net cancer tissu growth origin endocrin hormon nervou system cell
mnet occur intestin also may develop pancrea lung part bodi
renal cell carcinoma rcc kidney cancer origin small tubul transport primari urin rcc common
type kidney cancer adult account case
pleas see import disclosur inform page report
